ARTICLE
|
doi:10.20944/preprints201908.0177.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
chronic myeloid leukemia; tyrosine kinase inhibitor; adverse drug event; quality of life; second-generation tyrosine kinase inhibitor; nilotinib
Online: 16 August 2019 (08:09:07 CEST)